EC

Conmed CorpDUS Conmed Stock Report

Last reporting period 30 Sep, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

2.351

Small

Exchange

XDUS - Boerse Duesseldorf

EC8.DU Stock Analysis

EC

Neutral

Based on Eyestock quantitative analysis, EC8.DU`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

55/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

262.6 %

Greatly undervalued

Market cap $B

2.351

Dividend yield

1.06 %

Shares outstanding

30.499 B

CONMED Corp. operates as a medical technology company, which engages in the development, manufacturing, and sale of surgical devices and related equipment. The company is headquartered in Largo, Florida and currently employs 4,100 full-time employees. The firm is focused on advancing the healing of soft tissue using its proprietary BioBrace Implant technology. The firm's product lines consist of orthopedic surgery and general surgery. Its orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures including dissociated horizontal deviation (DHD) and DHD vision technologies. Its general surgery consists of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products, as well as electrosurgical generators and related instruments. Its products used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology and gastroenterology.

View Section: Eyestock Rating